Clinical pharmacokinetics of candesartan

Clinical Pharmacokinetics

Volumn 41, Issue 1, 2002, Pages 7-17

  Gleiter, Christoph H ^a   Mörike, Klaus E ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; CV 15959; DIGOXIN; GLIBENCLAMIDE; NIFEDIPINE; PRODRUG;

ANALYTIC METHOD; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FOOD DRUG INTERACTION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER FAILURE; PRIORITY JOURNAL; REVIEW;

EID: 0036168946     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241010-00002     Document Type: Review

References (30)

1. Angiotensin II receptor antagonists
2. Angiotensin receptor antagonists as a treatment for hypertension
3. Pharmacology of angiotensin II receptor antagonists: Comparison with renin inhibitors and angiotensin-converting enzyme inhibitors
4. Candesartan cilexetil: A review of its use in essential hypertension
5. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
6. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study
7. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil
8. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
9. Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine
10. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection
11. Development and validation of column-switching high-performance chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine
12. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers
13. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
14. 14C-candesartan cilexetil in healthy volunteers
15. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis
16. In vitro screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists
17. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function
18. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil
19. Clinical application of a new potent angiotensin II receptor antagonist. TCV-116
20. Pharmacokinetic drug interaction studies with candesartan cilexetil
21. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan
22. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis
23. Candesartan cilexetil: A comparison of once-daily versus twice-daily administration for systemic hypertension
24. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
25. Effective dose range of candesartan cilexetil for systemic hypertension
26. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function
27. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
28. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
29. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man
30. Comparison of the effects of candesartan and losartan on ambulatory blood pressure in patients with essential ambulatory hypertension: A forced titration study